As the number and price of novel medical treatments accelerate, there is heightened interest in determining their value. A price typically reflects a manufacturer’s estimate of society’s willingness to pay for their product. Treatments that improve survival appropriately command higher prices, although the correlation is not close, as noted by recent prices of proprotein convertase subtilisin/kexin type 9 inhibitors, sodium-glucose contransporter 2 inhibitors, combined sacubitril-valsartan, and transthyretin tetramer stabilizer therapy. Most of us accept that society should pay extra for a treatment that improves survival, but what about therapies that have as their main effect an improvement in health status?

随着新型医学疗法的数量和价格的增加，人们对确定它们的价值越来越感兴趣。价格通常反映了制造商对社会愿意为其产品付费的估计。适当提高生存率的治疗需要更高的价格，尽管相关性并不密切，正如最近前蛋白转化酶枯草杆菌蛋白酶/kexin 9 型抑制剂、钠-葡萄糖转运蛋白 2 抑制剂、沙库巴曲缬沙坦联合和甲状腺素四聚体稳定剂治疗的价格所指出的那样。我们大多数人都接受社会应该为提高生存率的治疗支付额外费用，但是以改善健康状况为主要效果的治疗呢？